Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Interventional × GIST × Clear all

Phase

Status

Completed 2 Unknown 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1204 Neoplasms 911 Carcinoma, Non-Small-Cell Lung 776 Prostatic Neoplasms 669 Colorectal Neoplasms 596 Lung Neoplasms 489 Leukemia, Myeloid, Acute 422 Pancreatic Neoplasms 393 Neoplasm Metastasis 379 Carcinoma, Hepatocellular 365 Ovarian Neoplasms 350 Multiple Myeloma 350 Stomach Neoplasms 338 Recurrence 326 Squamous Cell Carcinoma of Head and Neck 285 Melanoma 272 Uterine Cervical Neoplasms 256 Brain Neoplasms 244 Triple Negative Breast Neoplasms 237 Head and Neck Neoplasms 234 Precursor Cell Lymphoblastic Leukemia-Lymphoma 233 Glioblastoma 230 Lymphoma 223 Endometrial Neoplasms 215 Esophageal Neoplasms 209 Rectal Neoplasms 199 Sarcoma 194 Carcinoma, Renal Cell 184 Lymphoma, Non-Hodgkin 180 Colonic Neoplasms 177

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡